Safety of Budesonide Inhalation Suspension (Pulmicort Respules) after up to 52 Weeks of Treatment in Infants and Young Children with Persistent Asthma

Authors: Leflein, Jeffrey G.; Gawchik, Sandra M.; Galant, Stanley P.; Lyzell, Ewa; Young, Mike; Cruz-Rivera, Mario; Walton-Bowen, Karen; Smith, Joseph A.; Fitzpatrick, Sherahe

Source: Allergy and Asthma Proceedings, Volume 22, Number 6, November-December 2001 , pp. 359-366(8)

Publisher: OceanSide Publications, Inc

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Three open-label extension trials evaluated the safety of budesonide inhalation suspension (BIS; Pulmicort Respules) in 670 children (8 months-9 years of age) with mild-to-severe persistent asthma. Patients were randomized to receive either BIS or conventional asthma therapy (CAT) for 52 weeks. The percentage of patients who discontinued because of clinical adverse events was low and similar among the CAT (0.4%) and BIS (0.7%) groups. After adjusting for length of time in the studies, there were no clinically relevant differences between the BIS and CAT groups in the type, incidence, or intensity of adverse events; vital signs or physical examination outcomes; or changes in clinical laboratory evaluations or oral fungal cultures.

Document Type: Regular paper

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$25.00 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A